Prime Medicine (PRME) officer awarded 140,000 stock options vesting from 2026

Rhea-AI Filing Summary

Prime Medicine, Inc. reported that officer Alenson Carman acquired a stock option covering 140,000 shares of the company’s stock. This was recorded as a grant or award transaction.

According to the vesting terms, 1/48th of the option vests in substantially equal monthly installments on each monthly anniversary of February 23, 2026, conditioned on Carman’s continued service on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Alenson Carman

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	140,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 140,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alenson Carman

(Last) (First) (Middle)

C/O PRIME MEDICINE, INC.

60 FIRST STREET

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Prime Medicine, Inc. [ PRME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.34	02/23/2026		A		140,000		(1)	02/23/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 23, 2026, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

SVP, Finance and Chief Accounting Officer

	/s/ Ryan Brown, attorney-in-fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Prime Medicine (PRME) report for Alenson Carman?

Prime Medicine reported that officer Alenson Carman received a grant of stock options covering 140,000 shares. The Form 4 classifies this as a grant, award, or other acquisition, increasing his directly held derivative securities to 140,000 options following the transaction.

How many Prime Medicine (PRME) shares are covered by Carman’s new stock option?

The stock option granted to Alenson Carman covers 140,000 shares of Prime Medicine common stock. This entire amount is reported as directly owned derivative securities following the transaction, according to the Form 4 insider filing data provided.

What is the vesting schedule for Alenson Carman’s Prime Medicine (PRME) stock option?

The option vests over time, with 1/48th of the shares vesting in substantially equal monthly installments. Vesting occurs on each monthly anniversary of February 23, 2026, and each installment requires Carman’s continued service on the applicable vesting date.

Is Alenson Carman’s ownership in Prime Medicine (PRME) direct or indirect after this option grant?

The Form 4 indicates that Alenson Carman’s ownership of the reported stock option is direct. The derivative security is listed as directly owned, with total derivative securities following the transaction shown as 140,000 stock options.

What transaction code is used for Alenson Carman’s Prime Medicine (PRME) option grant?

The transaction uses code “A,” which represents a grant, award, or other acquisition. It is categorized as a derivative transaction involving a stock option, with the action described as a grant or award acquisition in the insider filing data.